Shanghai, China, September 16, 2020 -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has recently entered into a global development, manufacturing and commercialization collaboration with Wigen Biomedicine, a biomedical high-tech company committed to research and development of innovative drugs and new technologies, for Wigen’s 4 cancer drug candidates (XPO1 inhibitor, Aurora-A inhibitor, EGFR-exon20 inhibitor, and 4th generation EGFR inhibitor).
2020年10月29日，君实生物与药明康德、微境生物在上海签署战略合作协议，共同宣布在创新药研发领域开展战略合作。